SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

PF-08046040 is under clinical development by Pfizer and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Background: Acute myeloid leukemia (AML) is a hematologic tumor with poor prognosis and significant clinical heterogeneity. By integrating transcriptomic data, single-cell RNA sequencing data and ...

Analysts have set 12-month price targets for Chimerix, revealing an average target of $9.75, a high estimate of $11.00, and a low estimate of $6.00. Consistency is reflected as the current average ...

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

We, survivors, often express our gratitude for life, love, support and research, but what about the patients who do not ...

This is a significant departure from traditional cancer treatments that rely on killing cancer cells, often leading to severe ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...